文献速递血栓与止血贫血与红细胞疾病

免疫性血小板减少症患者缺血性卒中的临床特征与结局:多中心回顾性研究

Clinical profiling and outcomes of ischaemic stroke patients with immune thrombocytopenia: A multicentre retrospective study.
PubMed 文献 · Br J Haematol · 2026-06-01

ITP-AIS患者中位年龄65岁,女性居多,卒中时中位血小板计数44×10^9/L;梗死后抗血小板治疗占31.9%,出血转化5例(4.4%),死亡3例(2.7%)。多因素分析显示年龄>60岁、糖尿病、高血压、肾衰竭、吸烟和高LDL-C是ITP后AIS的独立危险因素。

要点

  • ITP患者发生AIS时血小板中位44×10^9/L,抗血小板治疗占31.9%,出血转化4.4%。
  • 年龄>60岁、糖尿病、高血压、肾衰竭、吸烟、高LDL-C为独立危险因素。
  • ITP相关治疗可能不增加ITP-AIS风险,管理需血液科与神经内科协作。

核心结论

  • ITP后发生AIS与年龄>60岁、糖尿病、高血压、肾衰竭、吸烟和高LDL-C独立相关。
  • ITP相关治疗可能不增加ITP-AIS风险,但需平衡抗栓获益与出血风险。

研究设计与样本

  • ITP-AIS队列中位年龄65岁(范围24-97岁),女性占61%,对照女性占52%。

主要发现

  • 卒中时中位血小板计数44×10^9/L(范围4-355×10^9/L)。
  • 梗死后治疗:抗血小板36例(31.9%)、抗凝4例(3.5%)、抗血小板联合抗凝4例(3.5%)、血管内取栓1例(0.9%)。
  • 出血转化5例(4.4%),死亡3例(2.7%),死因为颅内出血、消化道出血或严重肺部感染。
  • 多因素分析:年龄>60岁OR 3.12(95%CI 1.82-5.37,p<0.001),糖尿病OR 1.99(95%CI 1.13-3.52,p=0.018),高血压OR 2.75(95%CI 1.62-4.66,p<0.001),肾衰竭OR 3.00(95%CI 1.08-8.38,p=0.036),吸烟OR 5.02(95%CI 2.31-10.88,p<0.001),高LDL-C OR 2.34(95%CI 1.14-4.78,p=0.02)。

临床怎么用

  • 对ITP合并AIS患者应评估年龄、糖尿病、高血压、肾衰竭、吸烟和高LDL-C等危险因素。
  • 抗栓治疗需血液科与血管神经科协作,个体化平衡获益与出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To investigate the risk factors, treatment strategies and prognosis in patients with acute ischaemic stroke (AIS) after immune thrombocytopenia (ITP), we conducted a multicentre case-control study. One hundred and thirteen adult ITP patients with AIS were included, and each ITP-AIS was paired with three control subjects. The ITP-AIS cohort had a median age of 65 (24-97) years, was predominately female (61 vs. 52) and had a median platelet count of 44 × 109/L (range: 4-355 × 109/L) at the time of AIS. Post-infarction treatment included anti-platelet therapy (n = 36, 31.9%), anti-coagulation therapy (n = 4, 3.5%), combined anti-platelet-anti-coagulation therapy (n = 4, 3.5%) and endovascular thrombectomy (n = 1, 0.9%). Haemorrhagic transformation occurred in 5 (4.4%) patients. Three patients (2.7%) died due to intracranial haemorrhage, gastrointestinal haemorrhage or severe pulmonary infection. Multivariate analysis revealed that age greater than 60 years (p < 0.001; odds ratio [OR] 3.12; 95% confidence interval [CI] 1.82-5.37), diabetes mellitus (p = 0.018; OR 1.99; 95% CI 1.13-3.52), hypertension (p < 0.001; OR 2.75; 95% CI 1.62-4.66), renal failure (p = 0.036; OR 3.00; 95% CI 1.08-8.38), smoking (p < 0.001; OR 5.02; 95% CI 2.31-10.88) and hyper-low-density lipoprotein (LDL)-C (p = 0.02; OR 2.34; 95% CI, 1.14-4.78) were independent risk factors for AIS after ITP. This study revealed that ITP-related treatments might not increase the risk of ITP-AIS. The management of ITP-AIS patients requires close collaboration between haematologists and vascular neurologists to carefully balance therapeutic benefits against the risk of haemorrhagic complications.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cao L, Wu J, An Z, et al. Clinical profiling and outcomes of ischaemic stroke patients with immune thrombocytopenia: A multicentre retrospective study. Br J Haematol. 2026. PMID: 42223019. doi:10.1111/bjh.70572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。